The Global Myasthenia Gravis Market is projected to reach $3.14 billion by 2028, from a value of $1.76 billion in 2022, by registering a CAGR of 10.1% during the forecast period. Increasing prevalence of myasthenia gravis disorder globally, growing number of clinical studies for treatment of rare illnesses, increasing focus on development of healthcare infrastructure, and rising geriatric population are the major factors propelling the growth of the market. However, increasing availability of low-cost alternatives to branded treatments and adverse health effect such as severe muscular cramping in patients due to high-dose combination are hampering market growth. Moreover, increase in number of clinical trials for treatment of myasthenia gravis and increased research and development activities and massive investments are creating ample opportunities across the globe.

Recent Developments

In December 2021, Argenx which was working on the creation of treatment for generalized myasthenia gravis called “VYVGART”, announced that the U.S Food and Drug Administration (FDA) approved VYVGART’s use for the treatment of generalized myasthenia gravis (gMG) in adult patients.

In March 2021, Horizon Therapeutics plc acquired Viela Bio, Inc. with the aim to strengthen the portfolio, pipeline and therapeutic focus on rare disease treatments. The Viela acquisition provides multiple opportunities to drive long-term growth and solidify the future as an innovation-driven biotech company.

In October 2019, Ra Pharmaceuticals Inc. and UCB entered into merger agreement in which UCB acquired Ra Pharma to enhance the treatment option for the people living with myasthenia gravis and other rare diseases.

In October 2017, Alexion Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved eculizumab (brand name Soliris) as a treatment for adult patients with generalized Myasthenia Gravis (gMG) who are anti-acetylcholine receptor antibody-positive. Soliris is the first in a new class of drugs to be approved for MG in the U.S.

Competitive Landscape

Avadel Pharmaceuticals, Plc., Baxter International, Inc., Alexion Pharmaceutical Inc., Astellas Pharma, Novartis AG, Valent Pharmaceuticals, Grifols S.A., Catalyst Pharmaceuticals, F.Hoffmann-La Roche AG, Takeda Pharmaceutical Company, Pfizer, Inc., Mitsubishi Tanabe Pharma, GlaxoSmithKline Plc., Boston Scientific Corporation, GE Healthcare, Koninklijke Philips N.V., Argenx, Ra Pharmaceuticals Inc., and Horizon Therapeutics plc are some of the major players in the global Myasthenia Gravis market.